Executive Summary of the updated version of “Omakase Lab 1 2018 – P&R Orphan Drugs (2012-2016)

//Executive Summary of the updated version of “Omakase Lab 1 2018 – P&R Orphan Drugs (2012-2016)

Executive Summary of the updated version of “Omakase Lab 1 2018 – P&R Orphan Drugs (2012-2016)

Omakase is delighted to share with you the Executive Summary of the updated version of “Omakase Lab 1 2018 – P&R Orphan Drugs (2012-2016)”, in which we have updated and analysed the criteria driving P&R decisions for Orphan Drugs (ODs) approved by the European Commission and authorised in Spain between 2012 & 2018.

A new and full report analysing ODs authorised up to December 2019, including drug cost information, will be available in January 2020. So, stay tuned!

Download the Executive Summary here: ODs Report 2012-2018 Final – Executive Summary

 

2019-09-03T13:37:02+00:00September 3rd, 2019|News|

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies